Genetic diagnosis and detection rates using C9orf72 repeat expansion and a multi-gene panel in amyotrophic lateral sclerosis
Journal of Neurology · 2024
DOI: 10.1007/s00415-024-12368-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2024. Verfasst von Dalit Barel und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. dalitba@tlvmc.gov.il. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, C9orf72 Protein, DNA Repeat Expansion, Genetic Testing. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. It is mostly sporadic, with the C9orf72 repeat expansion being the most common genetic cause. While the prevalence of C9orf72-ALS in patients from different populations has been studied, data regarding the yield of C9orf72 compared to an ALS gene panel testing is limited.We aimed to explore the application of C9orf72 versus a gene panel in the general Israeli population. A total of 140 ALS patients attended our Neurogenetics Clinic throughout 2018-2023. Disease onset was between ages 60 and 69 years for most patients (34%); however, a quarter had an early-onset disease (< 50 years). Overall, 119 patients (85%) were genetically evaluated: 116 (97%) were tested for the C9orf72 repeat expansion and 64 (54%) underwent gene panel testing. The C9orf72 repeat expansion had a prevalence of 21% among Ashkenazi Jewish patients compared to 5.7% in non-Ashkenazi patients, while the gene panel had a higher yield in non-Ashkenazi patients with 14% disease-causing variants compared to 5.7% in Ashkenazi Jews. Among early-onset ALS patients, panel testing was positive in 12% compared to 2.9% for C9orf72.We suggest a testing strategy for the Israeli ALS patients: C9orf72 should be the first-tier test in Ashkenazi Jewish patients, while a gene panel should be considered as the first step in non-Ashkenazi and early-onset patients. Tiered testing has important implications for patient management, including prognosis, ongoing clinical trials, and prevention in future generations. Similar studies should be implemented worldwide to uncover the diverse ALS genetic architecture and facilitate tailored care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. dalitba@tlvmc.gov.il.
- The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Faculty of Medical and Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. hagitbf@tlvmc.gov.il.
- Faculty of Medical and Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel. hagitbf@tlvmc.gov.il.
Zitieren
APA
Barel, D., Marom, D., Ponger, P., Kurolap, A., Bar-Shira, A., Kaplan-Ber, I., Mory, A., Abramovich, B., Yaron, Y., Drory, V., & Baris Feldman, H. (2024). Genetic diagnosis and detection rates using C9orf72 repeat expansion and a multi-gene panel in amyotrophic lateral sclerosis. Journal of Neurology. https://doi.org/10.1007/s00415-024-12368-3
Vancouver
Barel D, Marom D, Ponger P, Kurolap A, Bar-Shira A, Kaplan-Ber I, et al. Genetic diagnosis and detection rates using C9orf72 repeat expansion and a multi-gene panel in amyotrophic lateral sclerosis. Journal of Neurology. 2024. doi:10.1007/s00415-024-12368-3
BibTeX
@article{Barel2024,
author = {Barel, Dalit and Marom, Daphna and Ponger, Penina and Kurolap, Alina and Bar-Shira, Anat and Kaplan-Ber, Idit and Mory, Adi and Abramovich, Beatrice and Yaron, Yuval and Drory, Vivian and Baris Feldman, Hagit},
title = {Genetic diagnosis and detection rates using C9orf72 repeat expansion and a multi-gene panel in amyotrophic lateral sclerosis},
journal = {Journal of Neurology},
year = {2024},
doi = {10.1007/s00415-024-12368-3}
}
EUVIMED